IntegraGen Reports Decline in Sales and Cash Reserves

IntegraGen, a company specializing in genomic analyses, announced its sales results for the first half of 2025, amounting to €2.5 million. This represents a 34% decrease compared to the first half of 2024. The drop was linked to reduced activity in microbiology and genomics platforms, primarily due to delays in project launches and a general slowdown in research projects. As of June 30, 2025, their cash position stood at €2.1 million, raising concerns about the continuity of operations beyond the first quarter of 2026 without new financing.

The company is exploring strategic options to reduce cash consumption, such as cutting operating costs and securing external financing. Despite challenges, IntegraGen aims to improve its situation by the third quarter with accelerated projects and potentially better funding conditions.